Gross visual inspection by endosonographers during endoscopic ultrasound-guided fine needle aspiration.


Journal

Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]
ISSN: 1424-3911
Titre abrégé: Pancreatology
Pays: Switzerland
ID NLM: 100966936

Informations de publication

Date de publication:
Jan 2019
Historique:
received: 25 06 2018
revised: 30 11 2018
accepted: 01 12 2018
pubmed: 12 12 2018
medline: 23 4 2019
entrez: 12 12 2018
Statut: ppublish

Résumé

A clear criterion for terminating endoscopic ultrasound fine needle aspiration (EUS-FNA) without rapid on-site evaluation (ROSE) has not been established. However, a possible solution includes gross visual inspection (GVI) of the sample obtained with EUS-FNA. We performed a retrospective study to elucidate the efficacy of GVI for the diagnostic yield of EUS-FNA. Patients who underwent EUS-FNA of a pancreatic mass using a standard 22-G needle from January 2017 to December 2017 were included in the study. At least two punctures were performed for each patient, and GVI was performed for each pass by endoscopists. The correlation between GVI and pathological findings were investigated per needle pass for the first two passes. Regarding GVI, we evaluated the presence of a visible core (with or without) and the sample quantity (large or small). We evaluated 126 EUS-FNA specimens and analyzed 252 needle passes. A final diagnosis of malignancy was made for 119 patients (94%). Accuracy rates were 92.5% with a visible core and 70.0% without a visible core (p < 0.01), and 85.2% for large sample quantities and 70.2% for small sample quantities (p < 0.01). Univariate analysis indicated that the presence of a visible core and large sample quantity were associated with accuracy. Multivariate analysis indicated that only the presence of a visible core was significant. GVI can predict the correct diagnosis when ROSE is unavailable. Evaluating the presence of a visible core is more sensitive than assessing the quantity of the sample obtained.

Sections du résumé

BACKGROUND/OBJECTIVES OBJECTIVE
A clear criterion for terminating endoscopic ultrasound fine needle aspiration (EUS-FNA) without rapid on-site evaluation (ROSE) has not been established. However, a possible solution includes gross visual inspection (GVI) of the sample obtained with EUS-FNA. We performed a retrospective study to elucidate the efficacy of GVI for the diagnostic yield of EUS-FNA.
METHODS METHODS
Patients who underwent EUS-FNA of a pancreatic mass using a standard 22-G needle from January 2017 to December 2017 were included in the study. At least two punctures were performed for each patient, and GVI was performed for each pass by endoscopists. The correlation between GVI and pathological findings were investigated per needle pass for the first two passes. Regarding GVI, we evaluated the presence of a visible core (with or without) and the sample quantity (large or small).
RESULTS RESULTS
We evaluated 126 EUS-FNA specimens and analyzed 252 needle passes. A final diagnosis of malignancy was made for 119 patients (94%). Accuracy rates were 92.5% with a visible core and 70.0% without a visible core (p < 0.01), and 85.2% for large sample quantities and 70.2% for small sample quantities (p < 0.01). Univariate analysis indicated that the presence of a visible core and large sample quantity were associated with accuracy. Multivariate analysis indicated that only the presence of a visible core was significant.
CONCLUSIONS CONCLUSIONS
GVI can predict the correct diagnosis when ROSE is unavailable. Evaluating the presence of a visible core is more sensitive than assessing the quantity of the sample obtained.

Identifiants

pubmed: 30528644
pii: S1424-3903(18)30762-2
doi: 10.1016/j.pan.2018.12.001
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

191-195

Informations de copyright

Copyright © 2018 IAP and EPC. Published by Elsevier B.V. All rights reserved.

Auteurs

Hirotoshi Ishiwatari (H)

Division of Endoscopy, Shizuoka Cancer Center, Shizuoka, Japan. Electronic address: ishihiro481019@gmail.com.

Junya Sato (J)

Division of Endoscopy, Shizuoka Cancer Center, Shizuoka, Japan.

Shinya Fujie (S)

Division of Endoscopy, Shizuoka Cancer Center, Shizuoka, Japan.

Keiko Sasaki (K)

Division of Pathology, Shizuoka Cancer Center, Shizuoka, Japan.

Junichi Kaneko (J)

Division of Endoscopy, Shizuoka Cancer Center, Shizuoka, Japan.

Tatsunori Satoh (T)

Division of Endoscopy, Shizuoka Cancer Center, Shizuoka, Japan.

Hiroyuki Matsubayashi (H)

Division of Endoscopy, Shizuoka Cancer Center, Shizuoka, Japan.

Yoshihiro Kishida (Y)

Division of Endoscopy, Shizuoka Cancer Center, Shizuoka, Japan.

Masao Yoshida (M)

Division of Endoscopy, Shizuoka Cancer Center, Shizuoka, Japan.

Sayo Ito (S)

Division of Endoscopy, Shizuoka Cancer Center, Shizuoka, Japan.

Noboru Kawata (N)

Division of Endoscopy, Shizuoka Cancer Center, Shizuoka, Japan.

Kenichiro Imai (K)

Division of Endoscopy, Shizuoka Cancer Center, Shizuoka, Japan.

Naomi Kakushima (N)

Division of Endoscopy, Shizuoka Cancer Center, Shizuoka, Japan.

Kohei Takizawa (K)

Division of Endoscopy, Shizuoka Cancer Center, Shizuoka, Japan.

Kinichi Hotta (K)

Division of Endoscopy, Shizuoka Cancer Center, Shizuoka, Japan.

Hiroyuki Ono (H)

Division of Endoscopy, Shizuoka Cancer Center, Shizuoka, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH